Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Atlab's ATL101 (Lutetium-177 anti-PSMA antibody) has demonstrated favourable safety profile and antitumor activity in Phase II study conducted in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC).
Subscribe to our email newsletter
The study observed a statistically significant relationship between injected dose and antitumor activity of the investigational agent.
ATLAB medical affairs head Pr. Jean-François Chatal said, "ATL101 shows a steep dose effect on antitumor activity as expected from its radiotherapy mode of action and a potential in prolonging the life of patients with metastatic prostate cancer."
All patients in three study cohorts had failed up to four hormonal therapies and 55% had failed minimum one docetaxel containing chemotherapy regimen, according to the company.
An increase from 13% in Cohort (1) to 47 % in Cohort (2) was noted in percentage of patients achieving PSA decline over 30%.
The rates of 30% PSA decline at 47% of patients were confirmed in the expansion Cohort 3.
Treatment effect was observed on the circulating tumour cells count. Treatment was well tolerated in the study.
A significant improvement in median overall survival with the injected dose of radioactivity from 11.9 months in cohort (1) to 21.8 months in cohorts 2 and 3 was reported.